269 related articles for article (PubMed ID: 25712076)
1. Monoclonal antibody-functionalized multilayered particles: targeting cancer cells in the presence of protein coronas.
Dai Q; Yan Y; Ang CS; Kempe K; Kamphuis MM; Dodds SJ; Caruso F
ACS Nano; 2015 Mar; 9(3):2876-85. PubMed ID: 25712076
[TBL] [Abstract][Full Text] [Related]
2. Influence of size, surface, cell line, and kinetic properties on the specific binding of A33 antigen-targeted multilayered particles and capsules to colorectal cancer cells.
Cortez C; Tomaskovic-Crook E; Johnston AP; Scott AM; Nice EC; Heath JK; Caruso F
ACS Nano; 2007 Sep; 1(2):93-102. PubMed ID: 19206525
[TBL] [Abstract][Full Text] [Related]
3. Improving Targeting of Metal-Phenolic Capsules by the Presence of Protein Coronas.
Ju Y; Dai Q; Cui J; Dai Y; Suma T; Richardson JJ; Caruso F
ACS Appl Mater Interfaces; 2016 Sep; 8(35):22914-22. PubMed ID: 27560314
[TBL] [Abstract][Full Text] [Related]
4. Cell-Conditioned Protein Coronas on Engineered Particles Influence Immune Responses.
Dai Q; Guo J; Yan Y; Ang CS; Bertleff-Zieschang N; Caruso F
Biomacromolecules; 2017 Feb; 18(2):431-439. PubMed ID: 28075126
[TBL] [Abstract][Full Text] [Related]
5. Macromolecule functionalization of disulfide-bonded polymer hydrogel capsules and cancer cell targeting.
Shimoni O; Postma A; Yan Y; Scott AM; Heath JK; Nice EC; Zelikin AN; Caruso F
ACS Nano; 2012 Feb; 6(2):1463-72. PubMed ID: 22260171
[TBL] [Abstract][Full Text] [Related]
6. In Vivo Biomolecule Corona around Blood-Circulating, Clinically Used and Antibody-Targeted Lipid Bilayer Nanoscale Vesicles.
Hadjidemetriou M; Al-Ahmady Z; Mazza M; Collins RF; Dawson K; Kostarelos K
ACS Nano; 2015 Aug; 9(8):8142-56. PubMed ID: 26135229
[TBL] [Abstract][Full Text] [Related]
7. Microfluidic Examination of the "Hard" Biomolecular Corona Formed on Engineered Particles in Different Biological Milieu.
Weiss ACG; Kempe K; Förster S; Caruso F
Biomacromolecules; 2018 Jul; 19(7):2580-2594. PubMed ID: 29668268
[TBL] [Abstract][Full Text] [Related]
8. Protease Degradation of Protein Coronas and Its Impact on Cancer Cells and Drug Payload Release.
Rodriguez-Quijada C; de Puig H; Sánchez-Purrà M; Yelleswarapu C; Evans JJ; Celli JP; Hamad-Schifferli K
ACS Appl Mater Interfaces; 2019 Apr; 11(16):14588-14596. PubMed ID: 30977626
[TBL] [Abstract][Full Text] [Related]
9. Protein Corona Formation on Colloidal Polymeric Nanoparticles and Polymeric Nanogels: Impact on Cellular Uptake, Toxicity, Immunogenicity, and Drug Release Properties.
Obst K; Yealland G; Balzus B; Miceli E; Dimde M; Weise C; Eravci M; Bodmeier R; Haag R; Calderón M; Charbaji N; Hedtrich S
Biomacromolecules; 2017 Jun; 18(6):1762-1771. PubMed ID: 28511014
[TBL] [Abstract][Full Text] [Related]
10. Corona Composition Can Affect the Mechanisms Cells Use to Internalize Nanoparticles.
Francia V; Yang K; Deville S; Reker-Smit C; Nelissen I; Salvati A
ACS Nano; 2019 Oct; 13(10):11107-11121. PubMed ID: 31525954
[TBL] [Abstract][Full Text] [Related]
11. Tuning the formation and degradation of layer-by-layer assembled polymer hydrogel microcapsules.
Becker AL; Zelikin AN; Johnston AP; Caruso F
Langmuir; 2009 Dec; 25(24):14079-85. PubMed ID: 20560555
[TBL] [Abstract][Full Text] [Related]
12. Exploiting the novel properties of protein coronas: emerging applications in nanomedicine.
Hamad-Schifferli K
Nanomedicine (Lond); 2015 May; 10(10):1663-74. PubMed ID: 26008198
[TBL] [Abstract][Full Text] [Related]
13. Differential roles of the protein corona in the cellular uptake of nanoporous polymer particles by monocyte and macrophage cell lines.
Yan Y; Gause KT; Kamphuis MM; Ang CS; O'Brien-Simpson NM; Lenzo JC; Reynolds EC; Nice EC; Caruso F
ACS Nano; 2013 Dec; 7(12):10960-70. PubMed ID: 24256422
[TBL] [Abstract][Full Text] [Related]
14. Specific targeting of tumor cells by lyophilisomes functionalized with antibodies.
van Bracht E; Stolle S; Hafmans TG; Boerman OC; Oosterwijk E; van Kuppevelt TH; Daamen WF
Eur J Pharm Biopharm; 2014 May; 87(1):80-9. PubMed ID: 24463217
[TBL] [Abstract][Full Text] [Related]
15. Evidence of protein coronas around soft nanoparticles regardless of the chemical nature of the outer surface: structural features and biological consequences.
de Castro CE; Panico K; Stangherlin LM; Albuquerque LJC; A S Ribeiro C; da Silva MCC; Jäger E; Giacomelli FC
J Mater Chem B; 2021 Mar; 9(8):2073-2083. PubMed ID: 33594396
[TBL] [Abstract][Full Text] [Related]
16. Corona-directed nucleic acid delivery into hepatic stellate cells for liver fibrosis therapy.
Zhang Z; Wang C; Zha Y; Hu W; Gao Z; Zang Y; Chen J; Zhang J; Dong L
ACS Nano; 2015 Mar; 9(3):2405-19. PubMed ID: 25587629
[TBL] [Abstract][Full Text] [Related]
17. Targeting Ability of Affibody-Functionalized Particles Is Enhanced by Albumin but Inhibited by Serum Coronas.
Dai Q; Yan Y; Guo J; Björnmalm M; Cui J; Sun H; Caruso F
ACS Macro Lett; 2015 Nov; 4(11):1259-1263. PubMed ID: 35614824
[TBL] [Abstract][Full Text] [Related]
18. Proteomic and Lipidomic Analysis of Nanoparticle Corona upon Contact with Lung Surfactant Reveals Differences in Protein, but Not Lipid Composition.
Raesch SS; Tenzer S; Storck W; Rurainski A; Selzer D; Ruge CA; Perez-Gil J; Schaefer UF; Lehr CM
ACS Nano; 2015 Dec; 9(12):11872-85. PubMed ID: 26575243
[TBL] [Abstract][Full Text] [Related]
19. Layer-by-Layer Engineered Polymer Capsules for Therapeutic Delivery.
Chandrawati R
Methods Mol Biol; 2018; 1758():73-84. PubMed ID: 29679323
[TBL] [Abstract][Full Text] [Related]
20. Targeting cancer cells: controlling the binding and internalization of antibody-functionalized capsules.
Johnston AP; Kamphuis MM; Such GK; Scott AM; Nice EC; Heath JK; Caruso F
ACS Nano; 2012 Aug; 6(8):6667-74. PubMed ID: 22872125
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
